| Trial ID: | L0998 |
| Source ID: | EUCTR2018-004431-79-FR
|
| Associated Drug: |
CC-90001
|
| Title: |
STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NONALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS
|
| Acronym: |
--
|
| Status: |
Prematurely Ended
|
| Study Results: |
--
|
| Results: |
--
|
| Conditions: |
Confirmed diagnosis of NASH and Stage 3 or Stage 4 fibrosis based upon the NASH Clinical Research Network (CRN) Histologic Scoring System and a nonalcoholic fatty liver disease (NAFLD) Activity Score (NAS) of 4 or higher, with a score of at least 1 for ea
|
| Interventions: |
CC-90001
|
| Outcome Measures: |
--
|
| Sponsor/Collaborators: |
Celgene Corporation
|
| Gender: |
All
|
| Age: |
18 Years to 64 Years ?? (Adult, Older Adult)
|
| Phases: |
Phase 2
|
| Enrollment: |
300
|
| Study Type: |
Therapeutic exploratory (Phase II)
|
| Study Designs: |
--
|
| Start Date: |
2019/7/2
|
| Completion Date: |
--
|
| Results First Posted: |
--
|
| Last Update Posted: |
--
|
| Locations: |
--
|
| URL: |
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004431-79
|
